Nadine Jackson McCleary, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colonic Neoplasms | 10 | 2022 | 2505 | 1.640 |
Why?
|
Colorectal Neoplasms | 14 | 2023 | 6748 | 1.260 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 950 | 0.990 |
Why?
|
Rectal Neoplasms | 3 | 2022 | 1165 | 0.960 |
Why?
|
Fluorouracil | 8 | 2022 | 1603 | 0.900 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 11585 | 0.680 |
Why?
|
Geriatric Assessment | 4 | 2017 | 1369 | 0.650 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2018 | 851 | 0.640 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2022 | 3478 | 0.620 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 589 | 0.620 |
Why?
|
Electronic Health Records | 5 | 2023 | 4565 | 0.590 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 69 | 0.590 |
Why?
|
Self-Help Groups | 1 | 2018 | 185 | 0.580 |
Why?
|
Camptothecin | 5 | 2022 | 591 | 0.540 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 417 | 0.510 |
Why?
|
Bone Marrow Neoplasms | 1 | 2014 | 101 | 0.450 |
Why?
|
Data Collection | 2 | 2013 | 3297 | 0.440 |
Why?
|
Self Care | 1 | 2018 | 781 | 0.440 |
Why?
|
Leucovorin | 6 | 2022 | 623 | 0.430 |
Why?
|
Deoxycytidine | 3 | 2013 | 845 | 0.410 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2022 | 687 | 0.400 |
Why?
|
Adenocarcinoma | 6 | 2022 | 6302 | 0.380 |
Why?
|
Organoplatinum Compounds | 5 | 2019 | 402 | 0.330 |
Why?
|
Age Factors | 7 | 2017 | 18160 | 0.300 |
Why?
|
Neoplasms | 9 | 2022 | 21723 | 0.300 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10096 | 0.290 |
Why?
|
Pancreatic Neoplasms | 6 | 2023 | 5261 | 0.290 |
Why?
|
Quality Improvement | 2 | 2018 | 3741 | 0.270 |
Why?
|
Aged, 80 and over | 17 | 2022 | 57627 | 0.260 |
Why?
|
Patient Participation | 3 | 2020 | 1411 | 0.260 |
Why?
|
Esophageal Neoplasms | 3 | 2021 | 1617 | 0.260 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 429 | 0.240 |
Why?
|
Aged | 33 | 2024 | 164472 | 0.240 |
Why?
|
Electronics | 2 | 2022 | 320 | 0.230 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11079 | 0.230 |
Why?
|
Liver Neoplasms | 3 | 2014 | 4252 | 0.220 |
Why?
|
Research Design | 2 | 2022 | 6066 | 0.210 |
Why?
|
Quality of Life | 6 | 2024 | 12980 | 0.210 |
Why?
|
Communication Barriers | 2 | 2022 | 411 | 0.200 |
Why?
|
Triazoles | 2 | 2020 | 901 | 0.200 |
Why?
|
Humans | 57 | 2024 | 746897 | 0.200 |
Why?
|
Neoplasm Metastasis | 5 | 2017 | 4827 | 0.190 |
Why?
|
Antineoplastic Agents | 6 | 2022 | 13581 | 0.190 |
Why?
|
Middle Aged | 29 | 2024 | 214711 | 0.190 |
Why?
|
Disease-Free Survival | 9 | 2014 | 6791 | 0.190 |
Why?
|
Male | 33 | 2024 | 351556 | 0.180 |
Why?
|
Anus Neoplasms | 1 | 2024 | 327 | 0.180 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.170 |
Why?
|
Stomach Neoplasms | 2 | 2020 | 1361 | 0.170 |
Why?
|
Female | 33 | 2024 | 382617 | 0.170 |
Why?
|
Adult | 22 | 2024 | 215291 | 0.160 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2281 | 0.160 |
Why?
|
Neutropenia | 1 | 2023 | 883 | 0.150 |
Why?
|
Patient Selection | 1 | 2010 | 4197 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3068 | 0.150 |
Why?
|
Feasibility Studies | 3 | 2023 | 5096 | 0.140 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 326 | 0.140 |
Why?
|
Medical Oncology | 3 | 2023 | 2269 | 0.130 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2018 | 215 | 0.130 |
Why?
|
Palliative Care | 3 | 2020 | 3549 | 0.130 |
Why?
|
Prognosis | 8 | 2020 | 29088 | 0.120 |
Why?
|
Anemia, Myelophthisic | 1 | 2014 | 6 | 0.120 |
Why?
|
Comorbidity | 2 | 2022 | 10378 | 0.120 |
Why?
|
Tumor Lysis Syndrome | 1 | 2014 | 40 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2019 | 538 | 0.120 |
Why?
|
Emigrants and Immigrants | 1 | 2020 | 531 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 637 | 0.110 |
Why?
|
Leukemia | 1 | 2022 | 1500 | 0.110 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2014 | 187 | 0.110 |
Why?
|
Tegafur | 1 | 2013 | 36 | 0.110 |
Why?
|
Life Expectancy | 1 | 2020 | 1222 | 0.110 |
Why?
|
Focus Groups | 1 | 2018 | 1337 | 0.110 |
Why?
|
Minority Groups | 1 | 2020 | 1197 | 0.110 |
Why?
|
Phenylurea Compounds | 2 | 2013 | 528 | 0.110 |
Why?
|
Smoking | 1 | 2010 | 8983 | 0.110 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 166 | 0.110 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1582 | 0.100 |
Why?
|
Perception | 1 | 2018 | 1180 | 0.100 |
Why?
|
Diabetic Retinopathy | 1 | 2020 | 1246 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2014 | 2256 | 0.090 |
Why?
|
CpG Islands | 1 | 2015 | 1199 | 0.090 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9329 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1958 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1611 | 0.090 |
Why?
|
Informed Consent | 1 | 2017 | 982 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2030 | 0.090 |
Why?
|
Treatment Outcome | 10 | 2022 | 63767 | 0.090 |
Why?
|
Food Hypersensitivity | 1 | 2018 | 687 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 421 | 0.090 |
Why?
|
Survival Rate | 3 | 2019 | 12651 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2014 | 1823 | 0.080 |
Why?
|
Software | 1 | 2023 | 4401 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1400 | 0.080 |
Why?
|
Sirolimus | 2 | 2013 | 1532 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3697 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 3986 | 0.080 |
Why?
|
Colectomy | 1 | 2013 | 668 | 0.080 |
Why?
|
Safety | 1 | 2012 | 1151 | 0.080 |
Why?
|
Quinolines | 1 | 2013 | 744 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1673 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5699 | 0.070 |
Why?
|
Neuroendocrine Tumors | 1 | 2013 | 642 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2015 | 21702 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1355 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3324 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1322 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7281 | 0.060 |
Why?
|
Survival Analysis | 2 | 2021 | 10139 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1641 | 0.060 |
Why?
|
Risk Assessment | 4 | 2020 | 23470 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3203 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5331 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8522 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2228 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5574 | 0.060 |
Why?
|
Physicians | 2 | 2021 | 4537 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2019 | 4285 | 0.060 |
Why?
|
Mutation | 4 | 2023 | 29643 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2868 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5096 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2056 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5167 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6455 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2013 | 6463 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3475 | 0.050 |
Why?
|
DNA Methylation | 1 | 2015 | 4260 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 291 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 107 | 0.050 |
Why?
|
Pyridines | 1 | 2013 | 2844 | 0.050 |
Why?
|
Administration, Oral | 1 | 2009 | 3978 | 0.050 |
Why?
|
Prospective Studies | 3 | 2024 | 53276 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 621 | 0.050 |
Why?
|
Multimedia | 1 | 2020 | 74 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 380 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 637 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12281 | 0.040 |
Why?
|
Sulfonamides | 1 | 2009 | 1955 | 0.040 |
Why?
|
Decision Making | 1 | 2013 | 3856 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2024 | 78361 | 0.040 |
Why?
|
Pyrazoles | 1 | 2009 | 1991 | 0.040 |
Why?
|
Corylus | 1 | 2018 | 3 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 188 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10313 | 0.040 |
Why?
|
Penaeidae | 1 | 2018 | 22 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2010 | 2070 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6419 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 607 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 750 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 266 | 0.040 |
Why?
|
Databases, Factual | 1 | 2013 | 7814 | 0.040 |
Why?
|
Recurrence | 1 | 2010 | 8388 | 0.040 |
Why?
|
Pamphlets | 1 | 2017 | 71 | 0.040 |
Why?
|
Patients | 1 | 2023 | 898 | 0.040 |
Why?
|
Eggs | 1 | 2018 | 183 | 0.030 |
Why?
|
Culture | 1 | 2020 | 623 | 0.030 |
Why?
|
Odds Ratio | 2 | 2023 | 9600 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1824 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2024 | 1391 | 0.030 |
Why?
|
Paclitaxel | 1 | 2023 | 1693 | 0.030 |
Why?
|
Young Adult | 2 | 2021 | 57221 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2019 | 38812 | 0.030 |
Why?
|
Death | 1 | 2020 | 665 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 627 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2090 | 0.030 |
Why?
|
Milk | 1 | 2018 | 438 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12231 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6517 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2020 | 2608 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12021 | 0.030 |
Why?
|
Adolescent | 3 | 2021 | 86323 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5614 | 0.030 |
Why?
|
Video Recording | 1 | 2017 | 947 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 9192 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8610 | 0.020 |
Why?
|
Language | 1 | 2020 | 1490 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2919 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1482 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20139 | 0.020 |
Why?
|
Niacinamide | 1 | 2013 | 414 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2012 | 291 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2190 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3593 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2013 | 901 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 1980 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2676 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1815 | 0.020 |
Why?
|
Microsatellite Instability | 1 | 2013 | 697 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7214 | 0.020 |
Why?
|
Signal Transduction | 1 | 2013 | 23158 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8364 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1700 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 883 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2017 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3647 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1083 | 0.020 |
Why?
|
ras Proteins | 1 | 2013 | 1049 | 0.020 |
Why?
|
SEER Program | 1 | 2012 | 1514 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7685 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10745 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7941 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2589 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1272 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1690 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3239 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 21608 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 5467 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2021 | 14126 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6230 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6072 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5259 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15562 | 0.010 |
Why?
|
Risk Factors | 1 | 2010 | 72453 | 0.010 |
Why?
|
Animals | 3 | 2023 | 166593 | 0.010 |
Why?
|
Mice | 2 | 2023 | 80291 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4485 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3614 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13816 | 0.010 |
Why?
|
United States | 2 | 2022 | 70460 | 0.010 |
Why?
|
Cohort Studies | 1 | 2022 | 40540 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7382 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15010 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 11966 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13326 | 0.010 |
Why?
|
Medicare | 1 | 2012 | 6569 | 0.010 |
Why?
|